 While EGFR inhibitors have demonstrated activity against NSCLC their integration into first-line therapy in combination with standard agents has yielded disappointing results. There are many potential reasons for the disappointing results in these first-line studies A single-arm Phase I trial of cetuximab in combination with docetaxel suggested better efficacy in second-line therapy for NSCLC than docetaxel alone but this comes at the expense of some increased toxicity. Preliminary data indicate that cetuximab has single agent activity in this setting. The confidence intervals for this activity overlap the median time to progression of the current second-line cytotoxic therapy options compared in the Hanna study A clinically relevant question is- does concurrent cetuximab and pemetrexed significantly improve upon outcomes of cetuximab monotherapy followed by pemetrexed monotherapy?. 